Cancer Immunotherapy Trials Network 12: Pembrolizumab in HIV-Associated Kaposi Sarcoma
Journal of Clinical Oncology · 2025-02 · 43 (4) · 432-442
DOI: 10.1200/jco.24.00640 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Journal of Clinical Oncology, 2025-02. Verfasst von Kathryn Lurain und 26 weiteren Autor:innen. Beteiligte Einrichtung: HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Sarcoma, Kaposi, HIV Infections, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Intramural NIH HHS.
Abstract (Originalsprache)
PURPOSE Cancer Immunotherapy Trials Network 12 demonstrated safety of pembrolizumab in treating advanced cancer in people with HIV. Here, we report results of the Kaposi sarcoma (KS) cohort. METHODS In this multicenter phase I trial, we enrolled participants with HIV-associated KS on antiretroviral therapy with CD4 + ≥50 cells/μL and HIV plasma RNA
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
- University of Alabama at Birmingham, Birmingham, AL.
- Fred Hutchinson Cancer Center and University of Washington, Seattle, WA.
- Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, Bethesda, MD.
- Dana-Farber Cancer Institute, Boston, MA.
- University of California San Francisco, San Francisco, CA.
ORCID-Profile: Kathryn Lurain, Ramya Ramaswami, Vanessa Eulo, Gaurav Goyal, Manoj Menon, Thomas A Odeny, Elad Sharon, Michael J Wagner, Maher Abdul-Hay, Elena M Cornejo Castro, Wendell Miley, Judith Kaiser, Robert Yarchoan, Steven P Fling, Thomas S Uldrick
Förderung
- NCI NIH HHS
- Intramural NIH HHS
Zitieren
APA
Lurain, K., Ramaswami, R., Ekwede, I., Eulo, V., Goyal, G., Menon, M., Odeny, T. A., Sharon, E., Wagner, M. J., Wang, C. J., Bhardwaj, N., Friedlander, P. A., Abdul-Hay, M., Cornejo Castro, E. M., Labo, N., Marshall, V. A., Miley, W., Moore, K., Roshan, R., …, & Uldrick, T. S. (2025). Cancer Immunotherapy Trials Network 12: Pembrolizumab in HIV-Associated Kaposi Sarcoma. Journal of Clinical Oncology, 43(4), 432-442. https://doi.org/10.1200/jco.24.00640
Vancouver
Lurain K, Ramaswami R, Ekwede I, Eulo V, Goyal G, Menon M, et al. Cancer Immunotherapy Trials Network 12: Pembrolizumab in HIV-Associated Kaposi Sarcoma. Journal of Clinical Oncology. 2025;43(4):432-442. doi:10.1200/jco.24.00640
BibTeX
@article{Lurain2025,
author = {Lurain, Kathryn and Ramaswami, Ramya and Ekwede, Irene and Eulo, Vanessa and Goyal, Gaurav and Menon, Manoj and Odeny, Thomas A and Sharon, Elad and Wagner, Michael J and Wang, Chia-Ching Jackie and Bhardwaj, Nina and Friedlander, Philip A and Abdul-Hay, Maher and Cornejo Castro, Elena M and Labo, Nazzarena and Marshall, Vickie Ann and Miley, Wendell and Moore, Kyle and Roshan, Romin and Whitby, Denise and Kask, Angela Shaulov and Kaiser, Judith and Han, Emma and Wright, Anna and Yarchoan, Robert and Fling, Steven P and Uldrick, Thomas S},
title = {Cancer Immunotherapy Trials Network 12: Pembrolizumab in HIV-Associated Kaposi Sarcoma},
journal = {Journal of Clinical Oncology},
year = {2025},
volume = {43},
number = {4},
pages = {432--442},
doi = {10.1200/jco.24.00640}
}
EUVIMED